Saudi Arabia has built an integrated national ecosystem designed to accelerate the safe adoption of emerging medical technologies, the Kingdom’s top food and drug regulator told an international gathering of medical device authorities in Singapore. Prof. Hisham Aljadhey, Chief Executive Officer of the Saudi Food and Drug Authority (SFDA), made the remarks during the 30th Management Committee Meeting of the International Medical Device Regulators Forum (IMDRF), held from 14 to 18 September 2026 and hosted by Singapore’s Health Sciences Authority (HSA). Speaking on a high-level panel alongside the Chief Executive of the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and the Chief Executive Officer of Singapore’s HSA, Aljadhey outlined how the Kingdom is positioning itself as a global hub for medical innovation while upholding the highest standards of safety, effectiveness, and quality.
The SFDA CEO’s participation underscores Saudi Arabia’s growing influence in international regulatory affairs and reflects the Kingdom’s commitment to shaping global standards in a sector that is being transformed by artificial intelligence, digital health tools, and next-generation medical devices. The IMDRF, one of the most prominent international bodies dedicated to regulatory convergence in the medical device sector, brings together leading regulatory authorities twice a year to exchange best practices and establish harmonized regulatory frameworks. Saudi Arabia’s active role in this forum signals a strategic shift from simply adopting international standards to helping write them, a development with far-reaching implications for patients, innovators, and health systems across the region and beyond.
Context and Background
Why does a regulatory meeting in Singapore matter for patients in Riyadh, Jeddah, or NEOM? The answer lies in the increasingly global nature of medical technology, where a device approved in one jurisdiction can take years to reach patients in another because of differing regulatory requirements. The IMDRF was established precisely to address this challenge, creating a platform where regulators can align their approaches, reduce duplication, and build mutual trust in each other’s scientific assessments. For Saudi Arabia, participation in this forum is not merely diplomatic; it is a practical pathway to faster access to life-saving innovations for its citizens.
The SFDA, established in 2003 and reporting to the Saudi government, has evolved into one of the region’s most respected regulatory bodies. Under Vision 2030, the Kingdom’s comprehensive national transformation strategy, the SFDA has embraced digital transformation, data-driven oversight, and proactive engagement with emerging technologies. Its mandate covers food, drugs, medical devices, and cosmetics, making it a central player in Saudi Arabia’s healthcare ecosystem. The agency’s growing international profile reflects the Kingdom’s broader ambition to be a leader not only in energy and finance but also in health sciences and regulatory innovation.
Singapore’s HSA, which hosted the meeting, is widely regarded as one of the world’s most efficient and forward-looking regulators, making it a fitting venue for discussions on convergence. The presence of the MHRA’s chief executive alongside Aljadhey and the HSA leadership highlighted the trilateral nature of the dialogue, bringing together perspectives from Europe, Asia, and the Middle East. This kind of high-level engagement is essential at a time when medical technology is advancing faster than many regulatory frameworks can adapt.
Key Details
During the panel session, Aljadhey emphasized that as medical technology evolves rapidly, fostering greater global cooperation among regulatory authorities has become increasingly important to ensure timely access to innovation while maintaining the highest standards of safety, effectiveness, and quality. He explained that Saudi Arabia has an integrated ecosystem designed to enable emerging medical technologies, built in accordance with international best practices. This system leverages advanced digital infrastructure, trusted data governance, and forward-looking frameworks for artificial intelligence and cybersecurity, according to the SFDA CEO.
Central to this ecosystem are regulatory sandboxes and dedicated innovation pathways, which work together to transform promising concepts into safe, effective medical solutions capable of being deployed and scaled. Regulatory sandboxes allow innovators to test new products in a controlled environment under regulatory supervision, while innovation pathways provide structured routes for bringing breakthrough technologies to market. Together, these mechanisms reduce uncertainty for developers and accelerate patient access without compromising safety.
Aljadhey noted that the SFDA maintains a proactive, risk-based, data-driven, and lifecycle-oriented system. This approach means the agency does not simply react to applications but anticipates technological trends and adjusts its oversight accordingly. The SFDA is also strengthening pathways for emerging technologies, including innovative medical devices and AI-enabled applications, and is deploying these technologies within its own regulatory processes. In other words, the regulator is not just regulating innovation; it is using it. This dual role positions the SFDA as both a gatekeeper and an enabler, a balance that is increasingly essential in modern regulatory science.
He further emphasized that the IMDRF serves as an essential platform for early dialogue among regulatory authorities, helping clarify regulatory requirements for innovators, reduce unnecessary duplication, and most importantly strengthen scientific decision-making to support innovation and protect public health. Early dialogue is particularly valuable for small and medium-sized enterprises, which often lack the resources to navigate multiple regulatory systems simultaneously. By aligning requirements, the IMDRF reduces barriers to entry and fosters a more competitive and innovative global market.
International and Regional Impact
What does Saudi Arabia’s leadership in regulatory convergence mean for the broader Middle East? The Kingdom’s active participation in the IMDRF sets a precedent for other nations in the region, demonstrating that countries can play a constructive role in shaping global health governance. As the largest economy in the Arab world and the host of the Gulf Cooperation Council’s headquarters, Saudi Arabia’s regulatory decisions often influence neighboring markets. Its commitment to international best practices can therefore have a ripple effect, encouraging harmonization across the region and facilitating cross-border trade in medical technologies.
For international innovators, the message is clear: Saudi Arabia is open for business and committed to predictable, science-based regulation. The Kingdom’s integrated ecosystem, with its digital infrastructure and AI frameworks, offers a compelling proposition for companies seeking to introduce cutting-edge products in a rapidly growing market. The Middle East’s healthcare sector is expanding, driven by population growth, rising incomes, and increased government investment. By aligning with international standards, the SFDA reduces the time and cost of market entry, making the Kingdom an attractive destination for global medical technology firms.
The trilateral dialogue between the SFDA, MHRA, and HSA also signals a new era of regulatory diplomacy. In a world where health security is increasingly tied to technological sovereignty, partnerships among like-minded regulators can accelerate the adoption of innovations and improve pandemic preparedness. Saudi Arabia’s engagement in these discussions reflects its broader foreign policy objectives, which emphasize multilateral cooperation and the peaceful application of science and technology for human welfare.
Economic and Strategic Significance
Why should investors and industry watchers pay attention to regulatory developments? The answer lies in the economics of healthcare innovation. Regulatory clarity is a key determinant of where companies choose to launch new products. A predictable, efficient, and transparent regulatory environment can attract foreign direct investment, stimulate local research and development, and create high-skilled jobs. Saudi Arabia’s efforts to build such an environment are closely tied to its economic diversification goals under Vision 2030, which seeks to reduce dependence on oil and grow knowledge-based industries.
The medical device and digital health sectors are among the fastest-growing segments of the global healthcare market. By positioning itself as a regulatory pioneer, Saudi Arabia aims to capture a share of this growth, not only as a consumer but also as a producer and exporter of medical technologies. The Kingdom has already made significant investments in biotechnology, genomics, and digital health, and the SFDA’s innovation pathways are designed to support these sectors. Moreover, the agency’s use of AI in its own processes demonstrates a commitment to operational excellence that can serve as a model for other government entities.
Strategically, the SFDA’s international engagement enhances Saudi Arabia’s soft power. By contributing to global regulatory harmonization, the Kingdom builds goodwill and positions itself as a responsible stakeholder in the international community. This aligns with the leadership’s vision of a Saudi Arabia that is not only economically prosperous but also globally influential and forward-looking.
Vision 2030 Alignment
How does medical device regulation connect to Saudi Arabia’s long-term transformation? Vision 2030 encompasses ambitious goals for healthcare, including improving the quality and efficiency of health services, expanding access to care, and fostering innovation. The SFDA’s work directly supports these objectives by ensuring that safe and effective technologies reach patients quickly. The agency’s focus on emerging technologies, such as AI-enabled diagnostics and personalized medicine, aligns with the Vision’s emphasis on building a diversified, knowledge-based economy.
Furthermore, the Kingdom’s participation in the IMDRF reflects the Vision’s call for enhanced international cooperation and its commitment to playing a leading role in global affairs. As Saudi Arabia continues to invest in its healthcare infrastructure, including major projects like NEOM’s health and well-being sector, the demand for cutting-edge medical technologies will only grow. The SFDA’s integrated ecosystem ensures that the Kingdom is ready to meet this demand while maintaining the highest safety standards. In doing so, it contributes to a healthier, more prosperous future for the Kingdom and reinforces its position as a global leader in regulatory innovation.
20 Questions
Q1. What event did the SFDA CEO participate in?
A1. Prof. Hisham Aljadhey participated in the 30th Management Committee Meeting of the International Medical Device Regulators Forum, held from 14 to 18 September 2026 in Singapore and hosted by Singapore’s Health Sciences Authority.
Q2. Who is the CEO of the Saudi Food and Drug Authority?
A2. Prof. Hisham Aljadhey serves as the Chief Executive Officer of the Saudi Food and Drug Authority, the Kingdom’s national regulator for food, drugs, medical devices, and cosmetics.
Q3. What is the International Medical Device Regulators Forum?
A3. The IMDRF is a prominent international body dedicated to regulatory convergence in the medical device sector, bringing together leading regulatory authorities biannually to exchange best practices and establish harmonized regulatory frameworks.
Q4. Which other regulators joined the SFDA CEO on the panel?
A4. The Chief Executive of the UK’s Medicines and Healthcare products Regulatory Agency and the Chief Executive Officer of Singapore’s Health Sciences Authority joined Prof. Aljadhey for the panel discussion.
Q5. What did the SFDA CEO say about global cooperation?
A5. He stated that as medical technology evolves rapidly, fostering greater global cooperation among regulatory authorities is increasingly important to ensure timely access to innovation while maintaining high standards of safety, effectiveness, and quality.
Q6. What kind of ecosystem has Saudi Arabia built for medical technologies?
A6. Saudi Arabia has an integrated ecosystem designed to enable emerging medical technologies, built in accordance with international best practices and leveraging advanced digital infrastructure, trusted data governance, and forward-looking AI and cybersecurity frameworks.
Q7. What are regulatory sandboxes?
A7. Regulatory sandboxes are controlled environments where innovators can test new medical technologies under regulatory supervision, helping to transform promising concepts into safe, effective solutions that can be deployed and scaled.
Q8. How does the SFDA describe its regulatory approach?
A8. The SFDA maintains a proactive, risk-based, data-driven, and lifecycle-oriented system, while strengthening pathways for emerging technologies, including innovative medical devices and AI-enabled applications.
Q9. What role does the IMDRF play for innovators?
A9. The IMDRF serves as an essential platform for early dialogue among regulatory authorities, helping clarify regulatory requirements for innovators, reduce unnecessary duplication, and strengthen scientific decision-making to support innovation and protect public health.
Q10. Why is early dialogue important in medical device regulation?
A10. Early dialogue helps innovators understand regulatory expectations, reduces the time and cost of bringing products to market, and ensures that safety and efficacy are built into products from the outset.
Q11. How does Saudi Arabia’s participation benefit patients?
A11. By aligning with international standards, Saudi Arabia can accelerate access to innovative medical technologies for its citizens while ensuring these products meet rigorous safety, effectiveness, and quality benchmarks.
Q12. What is the significance of the SFDA using AI in its own processes?
A12. It demonstrates the agency’s commitment to operational excellence and positions it as a model for other government entities, showing that regulators can be both innovative and rigorous.
Q13. How does this relate to Vision 2030?
A13. Vision 2030 aims to improve healthcare quality and access, diversify the economy, and foster innovation. The SFDA’s work directly supports these goals by enabling safe, timely access to advanced medical technologies.
Q14. What are the economic benefits of a strong regulatory environment?
A14. A predictable and efficient regulatory environment can attract foreign direct investment, stimulate local research and development, create high-skilled jobs, and position the Kingdom as a hub for medical technology.
Q15. How does the SFDA’s approach compare to international best practices?
A15. The SFDA’s ecosystem is built in accordance with international best practices, incorporating digital infrastructure, data governance, and frameworks for AI and cybersecurity that align with leading global regulators.
Q16. What are innovation pathways?
A16. Innovation pathways are structured regulatory routes designed to expedite the review and approval of breakthrough medical technologies, ensuring they reach patients faster without compromising safety.
Q17. Why is regulatory convergence important for the Middle East?
A17. Regulatory convergence can facilitate cross-border trade in medical technologies, reduce duplication, and improve access to innovative products across the region, benefiting patients and healthcare systems alike.
Q18. What does Saudi Arabia’s leadership in the IMDRF signal?
A18. It signals the Kingdom’s growing influence in global health governance and its commitment to shaping international standards, reflecting its broader ambition to be a leader in science and technology.
Q19. How does the SFDA support local innovation?
A19. Through regulatory sandboxes, dedicated innovation pathways, and proactive engagement with developers, the SFDA helps local innovators navigate regulatory requirements and bring their products to market efficiently.
Q20. What is the forward-looking vision for Saudi Arabia’s medical technology sector?
A20. The Kingdom aims to be a global hub for medical innovation, leveraging its integrated regulatory ecosystem to attract investment, foster local research and development, and ensure patients have access to the latest safe and effective technologies.
Reader Feedback
We value your thoughts. Please share your feedback on this article.
Your feedback helps us improve our coverage.





